Metabolic Characterization of Space Occupying Lesions of the Brain

Recruiting Observational Study
Brain Tumor Glioma IDH Mutation
No Placebo Group Every participant receives an active treatment — no one gets a placebo. Healthy Volunteers Welcome You do not need to have the condition being studied to take part. No Study Drug Researchers observe your health over time — no experimental treatment is given.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 and older
Sex
Any
Study type
Observational
Participants needed
55 (estimated)
Sponsor
Insel Gruppe AG, University Hospital Bern · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
High field MR-technologies are expected to boost metabolic spectroscopic imaging (MRSI), but also CEST-MRI. This is due to the fact that increased SNR is available which can be used to increase the spatial resolution of all sequences, or reduction of measurement times. Recent findings has shown that MRSI can be used to evaluate the isocitrate dehydrogenase (IDH) status of gliomas, a brain tumor ty…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * Healthy people who are able to lie in the MR scanner for one hour; * Patients with suspected mass in the brain * Written informed consent Exclusion Criteria: * Persons under the age of 18 * Persons who are mentally unable to choose to participate * Pregnant women * Patients …
Contacts

Johannes Slotboom, PhD

+41316327469

johannes.slotboom@gmail.com

CONTACT

Marwan El-Koussy, MD

+41316320008

marwan.el-koussy@insel.ch

CONTACT